It would therefore be very interesting to test the efficacy of suramin in combination with trametinib, dabrafenib or other kinase inhibitors, commonly used in thyroid cancer therapy, and our RET/PTC3 mouse model is perfectly suited to do that in the future. Here, NCOA4 is linked to thyroid cancer.